索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]张晓钰,周根青,刘少稳.导管消融治疗心房颤动合并心力衰竭[J].国际心血管病杂志,2024,02:97-100.
点击复制

导管消融治疗心房颤动合并心力衰竭(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年02期
页码:
97-100
栏目:
综述
出版日期:
2024-03-25

文章信息/Info

Title:
-
作者:
张晓钰; 周根青; 刘少稳
200080 上海交通大学医学院附属第一人民医院心血管内科
Author(s):
-
关键词:
心房颤动; 心力衰竭; 导管消融
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.02.009
文献标识码:
-
摘要:
心房颤动（房颤）和心力衰竭（心衰）是临床常见的心血管疾病，二者互为因果，导致恶性循环。导管消融治疗房颤合并心衰不仅可以改善心功能、提高生活质量，还能改善临床预后、降低再住院率和病死率。应在房颤患者出现心衰症状前或在心衰早期进行导管消融，才能使患者获益更多。
Abstract:
-

参考文献/References

[1] Trulock KM, Narayan SM, Piccini JP. Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation[J]. J Am Coll Cardiol, 2014, 64(7):710-721.
[2] Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study[J]. Circulation, 2014, 129(8):837-847.
[3] Lalani GG, Schricker A, Gibson M, et al. Atrial conduction slows immediately before the onset of human atrial fibrillation: a bi-atrial contact mapping study of transitions to atrial fibrillation[J]. J Am Coll Cardiol, 2012, 59(6):595-606.
[4] Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study[J]. Circulation, 2003, 107(23):2920-2925.
[5] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5):373-498.
[6] Khand AU, Rankin AC, Kaye GC, et al. Systematic review of the management of atrial fibrillation in patients with heart failure[J]. Eur Heart J, 2000, 21(8):614-632.
[7] Healey JS, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study[J]. Lancet, 2016, 388(10050):1161-1169.
[8] Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J]. Eur Heart J, 2012, 33(21):2719-2747.
[9] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J, 2016, 37(38):2893-2962.
[10] Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation[J]. N Engl J Med, 2002, 347(23):1825-1833.
[11] Hagens VE, Vermeulen KM, TenVergert EM, et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation—results from the RAte Control versus Electrical cardioversion (RACE) study[J]. Eur Heart J, 2004, 25(17):1542-1549.
[12] Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure[J]. N Engl J Med, 2008, 358(25):2667-2677.
[13] Chen S, Pürerfellner H, Meyer C, et al. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data[J]. Eur Heart J, 2020, 41(30):2863-2873.
[14] Proietti R, Hadjis A, AlTurki A, et al. A systematic review on the progression of paroxysmal to persistent atrial fibrillation:shedding new light on the effects of catheter ablation[J]. JACC Clin Electrophysiol, 2015, 1(3):105-115.
[15] Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial)[J]. Circ Arrhythm Electrophysiol, 2014, 7(1):31-38.
[16] Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction:the CAMERA-MRI study[J]. J Am Coll Cardiol, 2017, 70(16):1949-1961.
[17] Prabhu S, Costello BT, Taylor AJ, et al. Regression of diffuse ventricular fibrosis following restoration of sinus rhythm with catheter ablation in patients with atrial fibrillation and systolic dysfunction: a substudy of the CAMERA MRI trial[J]. JACC Clin Electrophysiol, 2018, 4(8):999-1007.
[18] Kuck KH, Merkely B, Zahn R, et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial[J]. Circ Arrhythm Electrophysiol, 2019, 12(12):e007731.
[19] Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device:results from the AATAC multicenter randomized trial[J]. Circulation, 2016, 133(17):1637-1644.
[20] Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure[J]. N Engl J Med, 2018, 378(5):417-427.
[21] Parkash R, Wells GA, Rouleau J, et al. Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial[J]. Circulation, 2022, 145(23):1693-1704.
[22] Kelly JP, DeVore AD, Wu J, et al. Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from get with the guidelines-heart failure[J]. J Am Heart Assoc, 2019, 8(24):e011560.
[23] Fukui A, Tanino T, Yamaguchi T, et al. Catheter ablation of atrial fibrillation reduces heart failure rehospitalization in patients with heart failure with preserved ejection fraction[J]. J Cardiovasc Electrophysiol, 2020, 31(3):682-688.
[24] Aldaas OM, Lupercio F, Darden D, et al. Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction[J]. Am J Cardiol, 2021, 142:66-73.
[25] Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation[J]. N Engl J Med, 2020, 383(14):1305-1316.
[26] Rillig A, Magnussen C, Ozga AK, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure[J]. Circulation, 2021, 144(11):845-858.
[27] Sohns C, Zintl K, Zhao Y, et al. Impact of left ventricular function and heart failure symptoms on outcomes post ablation of atrial fibrillation in heart failure: CASTLE-AF trial[J]. Circ Arrhythm Electrophysiol, 2020, 13(10):e008461.
[28] Nomura Y, Harada M, Motoike Y, et al. Selvester QRS score predicts improvement of LVEF in atrial fibrillation patients with systolic heart failure[J]. Pacing Clin Electrophysiol, 2022, 45(5):619-628.
[29] Wen S, Pislaru SV, Lin G, et al. Association of postprocedural left atrial volume and reservoir function with outcomes in patients with atrial fibrillation undergoing catheter ablation[J]. J Am Soc Echocardiogr, 2022, 35(8):818-828. e3.
[30] Bergonti M, Spera F, Tijskens M, et al. A new prediction model for left ventricular systolic function recovery after catheter ablation of atrial fibrillation in patients with heart failure: the ANTWOORD Study[J]. Int J Cardiol, 2022, 358:45-50.
[31] Yu L, Jiang R, Sun Y, et al. Catheter ablation for persistent atrial fibrillation with left ventricular systolic dysfunction: who is the best candidate?[J]. Pacing Clin Electrophysiol, 2022, 45(5):629-638.
[32] Tavazzi L, Maggioni AP, Rapezzi C, et al. Heart failure and catheter ablation of atrial fibrillation: navigating the difficult waters of heart failure phenotypes[J]. Eur J Intern Med, 2022, 99:13-18.

备注/Memo

备注/Memo:
通信作者：刘少稳， E-mail：shaowen.liu@hotmail.com
更新日期/Last Update: 2024-03-25